EphA2 Antibody, anti-human, REAfinity™
Synonyms: Ephrin type-A receptor 2, Epithelial cell kinase, Tyrosine-protein kinase receptor ECK, Eck
RECOMBINANT EXTENDED VALIDATION
Clone:
REA1354 | 371805
Type of antibody:
Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for EphA2 Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
PE
PE-Vio 670
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-133-840, 130-133-775
Description:
A431 cells were stained with EphA2 antibodies or with the corresponding REA Control (S) antibodies (left image) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Application imageView details view details

Application imageView details view details
Extended validation for EphA2 Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA1354
SHM16
low
1E3
low
6F8
low

Cells were incubated with an excess of purified unconjugated EphA2 (REA1354) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Sensitivity
Performance comparison

Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.

Extended-Validation detailed information image
Extended-Validation detailed information image
Extended-Validation detailed information image

Flow cytometric comparison of different clones for EphA2. A mixture of human peripheral blood mononuclear cells (PBMCs) and A431 cells were stained with EphA2 antibodies and plotted against the side scatter. As a control, EphA2 antibody staining was omitted and cells were measured in the same channel. Flow cytometry analysis was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.

Extended-Validation detailed information image

Flow cytometric comparison of different clones for EphA2 shown as histograms

Fixation data

To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.

No fixation
Extended-Validation detailed information image
Post fixation
Extended-Validation detailed information image

Comparison of staining pattern on non-fixed and fixed cells using EphA2 (REA1354). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for EphA2 Antibody, anti-human, REAfinity™
Overview

Clone REA1354 recognizes the human EphA2 protein, a member of the ephrin receptor subfamily of tyrosine kinase family, which binds to GPI-anchored ephrin-A ligands. EphA2 is detected in brain and glioma tissue and glioma cell lines, and tissues with a high proportion of epithelial cells. An upregulation of EphA2 is found in breast, prostate, and colon cancer vascular endothelium. EphA2 is a potential marker for treating malignant tumors.

Additional information: Clone REA1354 displays negligible binding to Fc receptors.

Alternative names

Ephrin type-A receptor 2, Epithelial cell kinase, Tyrosine-protein kinase receptor ECK, Eck

Detailed product information

Technical specifications

Clone
REA1354
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies
Species reactivity
human
Antigen
EphA2
Molecular mass of antigen [kDa]
106
Distribution of antigen
tumor cells, tumor
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for EphA2 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for EphA2 Antibody, anti-human, REAfinity™
Publications
  1. Miao, H. et al. (2000) Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation. Nat. Cell Biol. 2 (2): 62-69
  2. Zhou, L. et al. (2021) EphA2 as a new target for breast cancer and its potential clinical application. Int J Clin Exp Pathol 14 (4): 484-492
  3. Liu, D. P. et al. (2007) Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK. Int. J. Oncol. 30 (4): 865-871
  4. Xiao, T. et al. (2020) Targeting EphA2 in cancer. J Hematol Oncol. 13 (1): 114-114